

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Antengene Corporation Limited
德琪醫藥有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 6996)

SUPPLEMENTAL ANNOUNCEMENT
CANCELLATION OF GRANT OF CERTAIN SHARE OPTIONS

Reference is made to the announcement of the Company dated August 27, 2021 (the “**Announcement**”) regarding the grant of a total number of 4,748,142 Share Options to certain eligible persons. This supplemental announcement should be read in conjunction with the Announcement. Unless the context otherwise requires, terms used in this announcement shall have the same meanings as those defined in the Announcement. The Company intends to supplement the Announcement with the following information.

The Board hereby announces that on September 1, 2021, after further consideration, it has decided to cancel the grant of 330,000 Share Options and accordingly, the total number of Share Options granted under the Announcement has been reduced to 4,418,142 Share Options. Such cancellation is consented by Dr. Jay Mei, the Executive Director and Chief Executive Officer. Among the total of 4,418,142 Share Options, 1,470,000 Share Options are granted to Directors and chief executives, the details of the grant are amended as follows:

Name of grantee	Relationship with the Company	Number of Share Options granted
Jay Mei	Executive Director and Chief Executive Officer	670,000
Donald A. Lung	Executive Director and Chief Financial Officer	100,000
John F. Chin	Executive Director and Chief Business Officer	80,000
Kevin P. Lynch	Executive Director and Chief Medical Officer	300,000
Mark J. Alles	Independent non-Executive Director	50,000
Jing Qian	Independent non-Executive Director	10,000
Sheng Tang	Independent non-Executive Director	10,000
Bo Shan	Chief Scientific Officer	150,000
Yiteng Liu	Chief Operating Officer	100,000

Save as disclosed above, all other information and content set out in the Announcement remain unchanged.

By Order of the Board
Antengene Corporation Limited
Dr. Jay Mei
Chairman

Hong Kong, September 1, 2021

As at the date of this announcement, the board of directors of the Company comprises Dr. Jay Mei, Mr. John F. Chin, Mr. Donald A. Lung and Dr. Kevin P. Lynch as executive directors; Dr. Kan Chen and Mr. Yanling Cao as non-executive directors; and Mr. Mark J. Alles, Ms. Jing Qian and Mr. Sheng Tang as independent non-executive directors.